Previously completed Phase 2A clinical study of PH10 demonstrated significant antidepressant effects without psychological side effects or safety concerns after only one week of administration SOUTH SAN FRANCISCO, Calif., Dec. 10, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a

Dr. Monti developed the innovative scientific platform that enabled the early research and development of VistaGen's PH94B and PH10, intranasal neuroactive steroid drug candidates (pherines) with potential for the rapid-onset treatment of anxiety and depression disorders, respectively SOUTH SAN

Positive FDA Meeting Sets Key Pathway for Pivotal PH94B Phase 3 Study in the Second Quarter of 2021 Received Over $17.5 Million Net Proceeds from PH94B Upfront License Payment and Public Offering of Common Stock Positive New Data from Second Preclinical Study of AV-101 in Combination with

New electrophysiological data demonstrate that PH94B does not directly modulate GABA (gamma aminobutyric acid) receptors SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety,

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced that senior management will participate in the

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced that the Company received written notification

New Results Complement Earlier Positive Preclinical Data Demonstrating Increase in Brain Concentration Effects SOUTH SAN FRANCISCO, Calif., Sept. 3, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression,

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced that the Company will be presenting at the

Company Received Over $17.5 Million Net Proceeds from PH94B Upfront License Payment and Public Offering of Common Stock Subsequent to Quarter-end Positive Meeting with the FDA Sets Key Aspects of Pivotal PH94B Phase 3 Study SOUTH SAN FRANCISCO, Calif., Aug.

SAN FRANCISCO, Aug. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the underwriters of its previously announced public